Elanco Animal Health Incorporated $ELAN Stock Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC lowered its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 12.4% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 2,275,577 shares of the company’s stock after selling 323,497 shares during the period. Douglas Lane & Associates LLC’s holdings in Elanco Animal Health were worth $50,950,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in ELAN. BlackRock Inc. acquired a new position in shares of Elanco Animal Health during the second quarter worth $1,202,198,000. Squarepoint Ops LLC purchased a new position in Elanco Animal Health during the 2nd quarter worth $3,279,000. S&CO Inc. purchased a new position in Elanco Animal Health during the 2nd quarter worth $2,738,000. Geneos Wealth Management Inc. raised its stake in Elanco Animal Health by 3,358.1% in the first quarter. Geneos Wealth Management Inc. now owns 202,747 shares of the company’s stock valued at $4,852,000 after buying an additional 196,884 shares during the last quarter. Finally, Louisiana State Employees Retirement System purchased a new stake in Elanco Animal Health in the first quarter valued at about $3,448,000. 97.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ELAN has been the topic of a number of research analyst reports. Morgan Stanley boosted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, September 30th. TD Cowen upped their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. UBS Group lifted their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus price target of $29.70.

Elanco Animal Health Stock Performance

Shares of ELAN stock traded up $0.30 during trading hours on Friday, hitting $22.84. The company’s stock had a trading volume of 678,423 shares, compared to its average volume of 5,633,295. The stock has a market cap of $11.41 billion, a PE ratio of -55.74, a price-to-earnings-growth ratio of 1.59 and a beta of 1.70. Elanco Animal Health Incorporated has a 12-month low of $19.40 and a 12-month high of $27.98. The company has a 50 day moving average of $23.47 and a 200 day moving average of $23.64. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same period in the previous year, the firm posted $0.26 earnings per share. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.13 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Michael J. Harrington purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was bought at an average cost of $21.82 per share, with a total value of $109,100.00. Following the completion of the acquisition, the director owned 131,451 shares of the company’s stock, valued at $2,868,260.82. The trade was a 3.95% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the stock in a transaction on Friday, August 7th. The stock was bought at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the transaction, the chief financial officer owned 137,516 shares in the company, valued at approximately $3,173,869.28. This represents a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have acquired 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is currently owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio includes veterinary pharmaceuticals, vaccines, parasiticides, nutritional products and other solutions designed to prevent and treat disease, improve animal well-being and support livestock productivity.

For companion animals, Elanco offers products addressing pain, osteoarthritis, dermatological conditions, infectious diseases and flea, tick and intestinal parasite control.